Last reviewed · How we verify
MG4101
At a glance
| Generic name | MG4101 |
|---|---|
| Also known as | allogeneic natural killer cells, Allogeneic natural killer cell, NK cell |
| Sponsor | GC Cell Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MG4101 for Refractory or Relapsed AML (PHASE2)
- Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL) (PHASE2)
- MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin (PHASE1, PHASE2)
- A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma (PHASE2)
- Recruiting Blood Donor With Allogeneic Natural Killer Cell (NA)
- to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MG4101 CI brief — competitive landscape report
- MG4101 updates RSS · CI watch RSS
- GC Cell Corporation portfolio CI